Entering text into the input field will update the search result below

Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q4 2017 Results - Earnings Call Transcript

Mar. 01, 2018 2:45 PM ETParatek Pharmaceuticals, Inc. (PRTK)
SA Transcripts profile picture
SA Transcripts
137.74K Followers

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2017 Results Earnings Conference Call March 1, 2018 8:30 AM ET

Executives

Paul Arndt - Managing Director, LifeSci Advisors

Michael Bigham - Chairman and CEO

Evan Loh - President, COO and Chief Medical Officer

Adam Woodrow - Chief Commercial Officer

Doug Pagán - CFO

Analysts

Brandon Folkes - Cantor Fitzgerald

Jeffrey Lin - Leerink Partners

Mike Ulz - Robert W. Baird

Kevin Kedra - Gabelli

Adnan Butt - Guggenheim Securities

Ed Arce with - Wainwright

Laura Chico - Raymond James

Robert Driscoll - Wedbush Securities

Bert Hazlett - BTIG

Operator

Greetings and welcome to the Paratek Pharmaceuticals Fourth Quarter Full Year 2017 Earnings Conference. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the call over to your host today, Mr. Paul Arndt, Managing Director for LifeSci Advisors. Please proceed, sir.

Paul Arndt

Thank you, Tonya. Good morning. This is Paul Arndt, Managing Director of LifeSci Advisors, Paratek’s Investor Relations firm. And I’d like to welcome you to Paratek’s fourth quarter and full year 2017 update and earnings conference call.

A press release with the Company’s fourth quarter and full year financial results was issued earlier this morning and can be found at www.paratekpharma.com. The agenda for today’s call is as follows: Michael Bigham, CEO and Chairman of the Board, will provide an overview of the company’s recent progress and near-term plans for the coming quarter. Evan Loh, President, Chief Operating Officer and Chief Medical Officer, will speak to the regulatory and development update for omadacycline and opportunity for the product as Paratek prepares for commercial launch. Adam Woodrow, Chief Commercial Officer, will review the Company’s commercial readiness activities, and Doug Pagán, Chief Financial Officer, will review the financials for the fourth quarter and

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.